In dairy cattle reproductive management, oxytetracycline uterine infusion products are manufactured as sterile aqueous solutions or low-viscosity suspensions in single-dose polypropylene or polyethylene intrauterine syringes, with fill volumes of 20 mL, 50 mL, or 60 mL and oxytetracycline base concentrations of 50 mg/mL or 100 mg/mL. The formulation addition ratio is therefore between 5.4% w/v and 10.8% w/v expressed as oxytetracycline hydrochloride, allowing an administered dose of 2.0–4.0 g oxytetracycline base per treated cow without re-sterilisation of the remaining dose. The vehicle is prepared from Water for Injections protected by nitrogen sparging; anhydrous citric acid and sodium citrate dihydrate are used at combined buffer concentrations of 0.5–2.0% w/v to hold pH at 5.5–6.2 after aseptic filling, thereby reducing uterine irritation while preventing the pH-dependent precipitation of oxytetracycline free base during refrigerated storage. A low-viscosity water-soluble polymer may be included at 0.2–1.0% w/v to increase endometrial retention time, but published data for specific commercial polymer grades in this particular indication are limited.

The downstream manufacturing sequence starts by heating Water for Injections to 35–40°C in a jacketed stainless-steel vessel purged with nitrogen to dissolved oxygen below 0.5 mg/L, because the tetracycline nucleus is oxidation-sensitive. Sodium formaldehyde sulfoxylate is dissolved at 0.1–0.5% w/v as antioxidant before oxytetracycline hydrochloride is added under high-shear overhead mixing at 1,500–2,500 rpm until fully dissolved. The batch is cooled to 20–25°C, adjusted to final volume, and clarified through a 0.45 µm polyethersulfone membrane followed by a 0.22 µm sterilising-grade polyvinylidene fluoride filter into a sterile receiving vessel. Filling occurs under ISO 14644-1 Grade A unidirectional airflow with automated syringe filling, plunger insertion, and tip-cap sealing. Terminal steam sterilisation is avoided because aqueous oxytetracycline formulations degrade at conventional autoclave temperatures; membrane filtration and aseptic processing are the controlling stability steps. Release testing includes sterility to USP <71>, bacterial endotoxin limits calculated from the maximum administered volume per kilogram and tested to USP <85>, pH to USP <791>, and assay against the current Ph. Eur. monograph for oxytetracycline hydrochloride. Terminal finished product types are single-use intrauterine syringes supplied in foil overwrap, with graduated barrel markings for dose fractioning.

Compliance for lactating dairy cattle follows Commission Regulation (EU) No 37/2010 Table 1, which lists oxytetracycline MRLs of 100 µg/kg in milk and 600 µg/kg in bovine kidney; United States registration data are established under 21 CFR 522.1660 where the infusion is treated as a parenteral dosage form. The operational boundary for this dosage form is the incompatibility with calcium-containing rinses, lactated Ringer's solution, and alkaline buffers because oxytetracycline chelates divalent cations and forms insoluble aggregates that can block syringe ports or reduce residual activity in the uterine lumen. Bulk tank inhibitor testing is not a substitute for the milk withdrawal time stated in the marketing authorization.

What pH and Temperature Window Prevents Free-Base Precipitation in Injectable OTC?

Injectable oxytetracycline hydrochloride products are formulated at 50 mg/mL, 100 mg/mL, and 200 mg/mL oxytetracycline base equivalents, corresponding to an addition ratio of 5.4–21.6 g of the hydrochloride salt per 100 mL of solution when the 1.08 mass conversion factor from base to hydrochloride is applied. The high-strength 200 mg/mL solution is held at pH 8.5–9.0 because pH values below 7.5 do not maintain the oxytetracycline base in a fully soluble complexed state, while pH values above 9.5 accelerate base-catalysed degradation of the tetracycline nucleus to anhydro and epi derivatives. Temperature is maintained at 20–25°C during pH adjustment and sterile filtration because solubility and degradation are strongly pH-temperature coupled; at 2–8°C the free base may begin to crystallise unless the complexing agent concentration is correct. The vehicle contains Water for Injections and propylene glycol at 10–50% v/v depending on strength; antioxidant systems are based on sodium formaldehyde sulfoxylate at 0.1–0.5% w/v, with or without sodium metabisulphite at 0.05–0.2% w/v, and the batch remains under nitrogen overlay from dissolution to filling. The exact proportions of complexing agents such as magnesium oxide and organic amines are proprietary to each marketing authorization; published data for this specific configuration are limited to regulatory summaries and patent examples.

During manufacture, the dissolution vessel is charged with Water for Injections and the antioxidant system, after which oxytetracycline hydrochloride is dispersed under moderate agitation and the complexing agent is added as a slurry. The mixture is held at pH 8.6 and pH 9.0 as two-point pH checkpoints to confirm complete complexation and to detect any delayed precipitation before final volume adjustment. The batch is recirculated through 0.45 µm and 0.22 µm membrane filters under controlled pressure and aseptically filled into amber Type II glass vials of 50 mL, 100 mL, or 250 mL under Grade A conditions. Release testing includes bacterial endotoxin by USP <85>, particulate matter by USP <788>, pH by USP <791>, and residual solvents according to VICH GL18 for propylene glycol and any organic amine components. The finished article is a clear amber solution in amber glass vials sealed with bromobutyl rubber stoppers and aluminium caps for intramuscular or subcutaneous administration.

The injectable route is approved for cattle and swine where marketing authorizations exist; 21 CFR 522.1660 provides the United States regulatory framework and Commission Regulation (EU) No 37/2010 Table 1 establishes MRLs in bovine and porcine tissues. Dilution with lactated Ringer's solution, isotonic saline containing calcium or magnesium, or any infusion containing multivalent cations must be avoided because visible precipitation is immediate and antimicrobial availability is reduced. Syringes and needles should be dry; residual cleaning agents and disinfectants with cationic surfactants may also destabilise the solution.

Across broiler, turkey, and weaned-pig operations, mass medication via drinking water commonly employs water-soluble oxytetracycline hydrochloride powders or effervescent granules containing 100 mg/g, 200 mg/g, or 500 mg/g oxytetracycline base equivalents. The dry-form addition ratio ranges from 10.8% w/w to 54.0% w/w oxytetracycline hydrochloride, with the balance composed of anhydrous glucose, sodium citrate dihydrate, citric acid anhydrous, and colloidal silica at 0.2–0.8% w/w as glidant and anti-caking agent. The citrate buffer is held at 0.5–2.5% w/w of total blend and serves two functions: it drives final reconstituted solution pH to 3.0–3.5, where oxytetracycline solubility is highest, and it partially sequesters hard-water calcium and magnesium ions that would otherwise form OTC–metal chelates with reduced antimicrobial bioavailability. Hard water with total hardness above 200 mg/L calcium carbonate equivalent should be acidulated before stock solution preparation, otherwise the precipitate deposits in drinking lines and nipple drinkers and produces dose under-delivery.

Dry blending is performed at 20–25°C and relative humidity below 40% because oxytetracycline hydrochloride adsorbs moisture and forms agglomerates that do not wet uniformly when added to water. The API is screened through a 500 µm mesh to break agglomerates, then pre-blended with one-third of the glucose carrier for 10 minutes before introduction to a ribbon blender. For effervescent granules, non-aqueous fluid-bed granulation is used with a povidone binder dissolved in an alcohol-based granulation liquid; residual alcohol is controlled under VICH GL18 and the granule is dried to loss on drying not more than 2.0% w/w by USP <921>. The finished powder is filled into heat-sealed multi-layer foil sachets or bulk pails containing desiccant; in-line checkweighers maintain fill weight and vacuum leak testers verify sachet seal integrity. Terminal finished product types are 50 g, 100 g, and 1 kg foil sachets for poultry houses, plus 25 kg bulk packs for pig farm treatment lines.

Release testing includes assay of oxytetracycline base equivalents, water content by USP <921>, dispersibility in simulated hard water, and microbial limits for non-sterile oral dosage forms by USP <61> and USP <62>. The United States registration sits under 21 CFR 520.1660 for oral dosage forms where applicable, and food-producing species MRLs are governed by Commission Regulation (EU) No 37/2010 Table 1. Stock solutions are not held longer than 24 hours in chlorinated water because oxidative degradation becomes measurable; the solution should be shaded from direct sunlight and consumed promptly to avoid potency loss in long pipeline runs.

When OTC Dihydrate Enters a Type A Medicated Article, Stepwise Dilution Becomes the Rate-Limiting Step

Oxytetracycline feed premixes are manufactured either as Type A medicated articles containing 55 g/kg, 110 g/kg, or 220 g/kg oxytetracycline base equivalents for subsequent dilution to Type B and Type C feed categories. The final medicated feed concentration is typically between 100 mg/kg and 800 mg/kg depending on species, indication, and national approval; the United States framework under 21 CFR 558.450 establishes approved species, claims, and withdrawal periods, while European feed hygiene obligations fall under Regulation (EC) No 183/2005 and tissue MRLs are fixed in Commission Regulation (EU) No 37/2010 Table 1. The addition ratio in the premix is achieved by dry blending oxytetracycline dihydrate onto a corn cob meal, rice hull, or calcium carbonate carrier using food-grade mineral oil at 0.5–2.0% w/w as a dust suppressant and segregation control agent. Carriers with alkaline pH above 8.0 or high cation exchange capacity are avoided because they accelerate oxytetracycline degradation and reduce the assayable drug content during storage.

The manufacturing line is segregated from non-medicated feed equipment and operates under a validated HACCP plan. A geometric preblend of oxytetracycline dihydrate and carrier is prepared at 1:5 and then 1:25 before the main ribbon mixer charge, which prevents drug-rich pockets and improves content uniformity across the batch. The ribbon mixer is filled to 60–70% of rated capacity, and the mixing time is established by tracer studies; discharge passes through a 1.0 mm screen to remove agglomerates before enclosed screw conveying to bagging bins. The environment is maintained at 20–25°C and relative humidity below 55% because moisture above this threshold converts the dihydrate powder into a sticky agglomerated mass and leads to assay non-uniformity in later feed dilution. Terminal finished product types are 25 kg paper bags with low-density polyethylene liners, 500 kg flexible intermediate bulk containers, and bulk delivery to integrated feed mills.

Carryover control is the dominant operational boundary because oxytetracycline residues can appear in subsequent non-medicated feed at concentrations that violate national residue limits. Flush batches are scheduled after each medicated run and the sequence is verified by drug residue testing before non-medicated feed is allowed on the same line. The assay, moisture, and blend uniformity release methods follow the applicable sections of 21 CFR 558.450 and the registrant's approved analytical methodology; there is no direct user-level dilution of Type A articles without appropriate licensure and dedicated mixing equipment.

Calf and Lamb Tablet Compression Under Low-Humidity Dry Granulation

Because oxytetracycline hydrochloride is hygroscopic and poorly compressible, tablet manufacturing for pre-ruminant calves and lambs is constrained by moisture uptake, dissolution, and friability rather than API potency alone. The addition ratio is 20–40% w/w for 250 mg and 500 mg base-equivalent tablets, leaving sufficient excipient mass to correct powder flow and compactability. Direct compression is rejected at this loading because the API has high elastic recovery, poor flow, and a tendency to stick to punch faces; dry granulation by slugging or roller compaction is used to produce granules with a median particle size of 0.25–0.5 mm and a bulk density of 0.55–0.75 g/mL. The formulation includes microcrystalline cellulose at 20–40% w/w, crospovidone at 2–5% w/w as disintegrant, and magnesium stearate at 0.5–1.0% w/w; the lubricant is mixed for only 2–3 minutes in the final step because over-lubrication coats granules and slows dissolution release.

Granulation is performed at 20–25°C and 35–40% relative humidity. The API is screened through an 800 µm mesh, blended with intragranular excipients for 15 minutes in a V-blender, compacted on a single-station press at 5–10 kN with flat-faced punches, and milled through a 500 µm screen. The granules are lubricated and compressed on a rotary tablet press with 13 mm round flat bevelled tooling at a compression force of 8–12 kN, targeting tablet hardness of 6–8 kp and friability not more than 0.5% w/w after 100 rotations according to Ph. Eur. 2.9.7. Dissolution release is evaluated in 0.1 M hydrochloric acid at 75 rpm using USP <711> apparatus 2; the acceptance criterion is set by the individual marketing authorization, with Q values commonly between 75% and 85% at 60 minutes. Uniformity of dosage units is controlled to USP <905>, and finished tablets are packed in alu-alu blisters or amber high-density polyethylene bottles containing silica gel desiccant.

The relevant compliance standard for oral oxytetracycline tablets in the United States is 21 CFR 520.1660 where the dosage form is registered for a specific food-producing or companion species, while the European MRL framework under Commission Regulation (EU) No 37/2010 Table 1 applies to food-producing species. The operational boundary is the pre-ruminant target population: oral oxytetracycline in adult ruminants can severely disrupt rumen fermentation, so tablets are not labeled for mature cattle or sheep with functional rumens. The tablets should not be split in high-humidity barn environments because exposed tablet cores absorb moisture and degrade before administration.

Capsule Shells Equilibrate to 30% RH Before OTC HCl Filling

Oxytetracycline hydrochloride capsules are manufactured in low-volume veterinary licensed units and compounding pharmacies for companion species and non-food horses, often in strengths of 100 mg, 250 mg, or 500 mg base equivalents. The formulation addition ratio is typically 15–50% w/w, with the final fill weight determined by capsule size and the bulk density of the lubricated blend. The API powder has an angle of repose above 45° and responds to moisture during storage, so the direct filling process requires colloidal silicon dioxide at 1.0–3.0% w/w as glidant and magnesium stearate or sodium stearyl fumarate at 0.5–1.5% w/w as lubricant. Capsule shells are equilibrated at 30% relative humidity for 24–48 hours before filling; shells below 20% RH become brittle and crack during closure, while shells above 45% RH swell and cause telescoping, powder leakage, and seal failure.

Blending is performed in a bin blender at 20–25°C and 30–40% relative humidity; wet granulation is not used because residual moisture promotes hydrolysis of the tetracycline ring system to anhydrotetracycline and epioxytetracycline degradation products that do not meet assay limits. Filling is carried out on a dosator or tamping-pin capsule machine with vacuum-assisted powder retention, followed by dedusting and in-line checkweighing. The filled capsules are packaged in amber high-density polyethylene bottles with silica gel or molecular sieve desiccant and induction-sealed closures to limit moisture ingress during transport. Release testing includes dissolution to USP <711>, uniformity of dosage units to USP <905>, disintegration to Ph. Eur. 2.9.1, and water content to USP <921> with a limit not more than 2.0% w/w for the powder blend.

Because food-producing species use is restricted by Commission Regulation (EU) No 37/2010 Table 1 MRLs and withdrawal requirements, the capsule format is normally reserved for companion animals, non-food horses, or authorized minor species where owners can administer a discrete dose. The operational boundary is moisture: bulk API and filled capsules must not be exposed to steam cleaning, high-humidity cool rooms, or open bench storage in tropical conditions without desiccant protection. Capsules should not be blended with calcium-containing fillers such as dibasic calcium phosphate because oxytetracycline chelates calcium and dissolution availability drops below the specification described in the approved method.